Cue Biopharma (CUE) EBIAT (2017 - 2025)
Cue Biopharma (CUE) has disclosed EBIAT for 9 consecutive years, with $1.6 million as the latest value for Q4 2025.
- Quarterly EBIAT rose 116.69% to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.6 million through Dec 2025, up 34.6% year-over-year, with the annual reading at -$26.6 million for FY2025, 34.6% up from the prior year.
- EBIAT hit $1.6 million in Q4 2025 for Cue Biopharma, up from -$7.4 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $1.6 million in Q4 2025 to a low of -$14.6 million in Q4 2022.
- Historically, EBIAT has averaged -$10.8 million across 5 years, with a median of -$11.6 million in 2023.
- Biggest five-year swings in EBIAT: plummeted 74.04% in 2022 and later skyrocketed 116.69% in 2025.
- Year by year, EBIAT stood at -$8.4 million in 2021, then tumbled by 74.04% to -$14.6 million in 2022, then grew by 7.94% to -$13.4 million in 2023, then grew by 29.31% to -$9.5 million in 2024, then soared by 116.69% to $1.6 million in 2025.
- Business Quant data shows EBIAT for CUE at $1.6 million in Q4 2025, -$7.4 million in Q3 2025, and -$8.5 million in Q2 2025.